CMS'(Centers for Medicare and Medicaid Services) "new tech" definition should not penalise innovators
This article was originally published in Clinica
The US device industry is calling for greater consistency in how Medicare defines a new technology so that breakthrough products are adequately priced when used within the hospital setting.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.